Diabetes Flashcards
What are the three rapid acting insulins?
Glulisine
Aspart
Lispro
Rapid acting insulin: indication?
For meals or acute hyperglycemia- inject immediately before meals
Regular insulin: indication?
For meals or acute hyperglycemia: needs to be injected 30-45 minutes before meals
NPH: indication
Provides basal insulin and overnight coverage
Name two long acting insulins
Glargine
Detmir
Glargine/detmir; indications?
Provides basal insulin and overnight coverage
Metformin: MOA?
Inhibition of mito complex I –> increased AMP –> decreased adenylate cyclase and increased AMPK
This OPPOSES glucagon and decreases hepatic gluconeogenesis (increases glucose utilization and insulin sensitivity)
What is the main advantage of metformin?
Lowers fasting glucose levels
Main side effect of metformin?
Lactic acidosis
Metformin: contraindications?
Renal insufficiency, MI, CHF
MOA of sulfonylureas?
Inhibition of beta cell K+ channels –> increased insulin secretion
What is the advantage of sulfonylureas?
Slow onset/long duration –> lowers fasting glucose
What is the main adverse effect associated with sulfonylureas?
Increased risk of hypoglycemia
Sulfonylureas: contraindications?
Renal/liver disease
Meglitinides: MOA?
Inhibition of K+ channels –> glucose-dependent insulin secretion
Meglitinides: advantages?
Fast acting, short duration to decrease postprandial glucose
Thiazolidinediones: MOA?
Agonist of PPARgamma TF
Increased insulin sensitivity
Increase glucose utilization
Decrease insulin resistance
Thiazolidinediones: advantages?
Lowers fasting glucose
Lowers triglycerides
Thiazolidinediones: Adverse effects?
Weight gain (subQ)
Fluid retention/edema
Increased HF Risk
Increased bone fractures in women
Pioglitazone and Rosiglitazone are what type of drugs?
thiazolidinediones
Name two alpha-glucosidase inhibitors
Acarbose, Miglitol
What is the MOA of the alpha-glucosidase inhibitors?
Inhibits the conversion of carbohydrates into monosaccharides/inhibits absorption
Name two incretin mimetics
Exenatide
Liraglutide
What is the MOA of exenatide/liraglutide?
Potentiates glucose-induced insulin release as a GLP-1 analog
Decreases pancreatic glucagon and decreases hepatic gluconeogenesis